Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Cannell & Spears LLC

Cannell & Spears LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 636.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,677 shares of the company's stock after buying an additional 31,696 shares during the quarter. Cannell & Spears LLC's holdings in Novo Nordisk A/S were worth $3,155,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares during the period. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Albion Financial Group UT boosted its holdings in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after buying an additional 278 shares during the last quarter. Sound Income Strategies LLC increased its stake in Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after buying an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 0.2 %

NVO stock traded up $0.17 during trading on Wednesday, reaching $68.20. 7,301,268 shares of the stock were exchanged, compared to its average volume of 5,588,193. The business has a 50 day moving average price of $81.89 and a 200-day moving average price of $97.68. Novo Nordisk A/S has a 1 year low of $66.71 and a 1 year high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $306.05 billion, a price-to-earnings ratio of 20.73, a P/E/G ratio of 0.90 and a beta of 0.42.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 47.72%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NVO. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Friday, March 21st. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.